|
Gerald Bisbee joined ReGen in 1998. Prior to ReGen, Dr. Bisbee was chairman and CEO of APACHE Medical Systems, Inc., a company providing clinical trial and FDA advisory services to device and pharmaceutical companies, and offering an industry-leading information management system for high-cost, high-risk patients. Following sale of the assets of APACHE, Dr. Bisbee became the Chairman of its successor corporation, AROS Corporation, which entered into a reverse merged transaction with ReGen to form ReGen Biologics, Inc. Prior to APACHE, Dr. Bisbee was Chairman and CEO of Sequel Corporation, an orthopaedic rehabilitation practice management and manufacturing company that became part of the Hanger Orthopedic Group. Dr. Bisbee holds a Ph.D. from Yale University in chronic disease epidemiology with an emphasis in musculo-skeletal disease. His dissertation is part of the development of DRGs. Dr. Bisbee is a co-author of the first national orthopaedic study entitled, Musculoskeletal Disorders: Their Frequency of Occurrence and Their Impact on the Population of the United States. He holds an M.B.A. from University of Pennsylvania’s Wharton School and a B.A. from North Central College. Dr. Bisbee is also a director of Cerner Corporation and Care Investment Trust. | 